Last reviewed · How we verify
Continuous heparin infusion
Continuous heparin infusion is a Anticoagulant Small molecule drug developed by Yong Seog Oh. It is currently in Phase 3 development for Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism), Acute coronary syndrome, Atrial fibrillation with thromboembolism risk.
Heparin is an anticoagulant that inhibits multiple clotting factors to prevent thrombus formation.
Heparin is an anticoagulant that inhibits multiple clotting factors to prevent thrombus formation. Used for Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism), Acute coronary syndrome, Atrial fibrillation with thromboembolism risk.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Continuous heparin infusion |
|---|---|
| Sponsor | Yong Seog Oh |
| Drug class | Anticoagulant |
| Target | Thrombin (Factor IIa), Factor Xa, Antithrombin III |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Heparin works by binding to antithrombin III, which then inactivates thrombin (Factor IIa) and Factor Xa, thereby interrupting the coagulation cascade. Continuous intravenous infusion maintains steady anticoagulant levels in the bloodstream, preventing clot formation and extension in acute thrombotic conditions.
Approved indications
- Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism)
- Acute coronary syndrome
- Atrial fibrillation with thromboembolism risk
- Prevention of thrombosis during cardiac surgery and extracorporeal circulation
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Thrombosis
- Osteoporosis (with prolonged use)
- Hyperkalemia
- Alopecia (with prolonged use)
Key clinical trials
- Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma (PHASE2)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System (PHASE2)
- Protocol-Driven Continuous Infusion Versus Intermittent Bolus Heparin During Atrial Fibrillation Ablation
- A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229 (PHASE1)
- Nafamostat Efficacy in Phase 3 Registrational CRRT Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous heparin infusion CI brief — competitive landscape report
- Continuous heparin infusion updates RSS · CI watch RSS
- Yong Seog Oh portfolio CI
Frequently asked questions about Continuous heparin infusion
What is Continuous heparin infusion?
How does Continuous heparin infusion work?
What is Continuous heparin infusion used for?
Who makes Continuous heparin infusion?
What drug class is Continuous heparin infusion in?
What development phase is Continuous heparin infusion in?
What are the side effects of Continuous heparin infusion?
What does Continuous heparin infusion target?
Related
- Drug class: All Anticoagulant drugs
- Target: All drugs targeting Thrombin (Factor IIa), Factor Xa, Antithrombin III
- Manufacturer: Yong Seog Oh — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism)
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Atrial fibrillation with thromboembolism risk
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing